Hodges, who is taking over the Operations Director role this week, will report directly to Jarl Severn, Managing Director. He succeeds Modestino Grazino, who is stepping down after almost eight years in the position.
Jarl Severn commented on the appointment, saying, “We are thrilled to have Garry join the company. Our operations are a core part of our ongoing success in the diagnostic and drug delivery markets. Over the years, Garry’s predecessor Modestino made valuable contributions, leading our expansion both in the UK and Malaysia, and helping to modernize our facilities.
“With Garry’s appointment, we will continue our commitment to building state-of-the-art production facilities. We are confident that his deep experience in implementing new technologies will help us meet our goals for quality and service, and steer our business strategy for the future. We look forward to benefiting from his expertise.”
Garry Hodges joins Owen Mumford from Aesica Pharmaceuticals, where he was Corporate Operations Director and led the Operations Excellence Program to improve quality and supply chain performance.
About his new role, Garry Hodges said, “I am really excited to join Owen Mumford. I’ve spent my career in technical and scientific roles, and I believe my background in operations and management will add to the company’s strong track record and support its future growth.”
For more information, contact: Gillian Gibbons, 07795 342804